Company intelligence / Profile preview

Wuxi Shansheng Pharmaceutical

Wuxi, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Wuxi Shansheng Pharmaceutical is a clinical-stage biopharmaceutical company based in Wuxi, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on therapeutic areas including metabolic diseases, particularly hyperuricemia and gout, as well as autoimmune disorders. Its lead candidate, SS-101, is a potent URAT1 inhibitor currently in clinical development for the treatment of chronic gout. Shansheng leverages its internal R&D capabilities to advance a pipeline of targeted therapies aimed at addressing significant unmet medical needs in the Chinese and global markets.

Therapeutic areas: Metabolic DisordersRheumatologyDermatologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Wuxi Shansheng Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuxi Shansheng Pharmaceutical.

Explore the full profile